Insys Therapeutics Inc. (NASDAQ:INSY)‘s stock had its “hold” rating reaffirmed by stock analysts at Oppenheimer Holdings Inc. in a research note issued to investors on Sunday.
A number of other research analysts also recently commented on INSY. Zacks Investment Research downgraded Insys Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 9th. Jefferies Group restated a “buy” rating and set a $22.00 price objective (up from $17.00) on shares of Insys Therapeutics in a research note on Thursday, August 4th. Royal Bank Of Canada lowered their price objective on Insys Therapeutics from $32.00 to $26.00 and set an “outperform” rating for the company in a research note on Thursday, September 22nd. RBC Capital Markets restated an “outperform” rating and set a $26.00 price objective (down from $32.00) on shares of Insys Therapeutics in a research note on Friday, September 23rd. Finally, Piper Jaffray Cos. restated an “overweight” rating and set a $28.00 price objective on shares of Insys Therapeutics in a research note on Thursday, August 25th. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $23.00.
Insys Therapeutics (NASDAQ:INSY) traded up 3.86% during midday trading on Friday, reaching $13.20. The company’s stock had a trading volume of 391,718 shares. Insys Therapeutics has a 1-year low of $10.01 and a 1-year high of $33.88. The company has a market capitalization of $947.36 billion, a price-to-earnings ratio of 42.58 and a beta of 0.94. The company’s 50-day moving average price is $12.04 and its 200-day moving average price is $14.05.
Insys Therapeutics (NASDAQ:INSY) last posted its quarterly earnings results on Thursday, November 3rd. The specialty pharmaceutical company reported $0.07 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.02 by $0.05. The business had revenue of $55.20 million for the quarter, compared to analyst estimates of $55.97 million. Insys Therapeutics had a return on equity of 9.39% and a net margin of 8.71%. The business’s revenue was down 39.5% compared to the same quarter last year. During the same period in the prior year, the company posted $0.50 EPS. On average, analysts predict that Insys Therapeutics will post $0.34 earnings per share for the current fiscal year.
In other Insys Therapeutics news, Director Steven J. Meyer purchased 10,000 shares of the firm’s stock in a transaction dated Friday, November 4th. The stock was bought at an average price of $10.75 per share, with a total value of $107,500.00. Following the completion of the purchase, the director now owns 44,083 shares in the company, valued at approximately $473,892.25. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 69.20% of the stock is owned by insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Legal & General Group Plc boosted its position in shares of Insys Therapeutics by 16.3% in the first quarter. Legal & General Group Plc now owns 6,247 shares of the specialty pharmaceutical company’s stock valued at $100,000 after buying an additional 876 shares in the last quarter. Cornerstone Capital Management Holdings LLC. purchased a new position in shares of Insys Therapeutics during the third quarter valued at $104,000. Stevens Capital Management LP purchased a new position in shares of Insys Therapeutics during the third quarter valued at $147,000. Prudential Financial Inc. boosted its position in shares of Insys Therapeutics by 6.1% in the first quarter. Prudential Financial Inc. now owns 10,370 shares of the specialty pharmaceutical company’s stock valued at $166,000 after buying an additional 600 shares in the last quarter. Finally, Parametric Portfolio Associates LLC boosted its position in shares of Insys Therapeutics by 18.1% in the second quarter. Parametric Portfolio Associates LLC now owns 15,197 shares of the specialty pharmaceutical company’s stock valued at $197,000 after buying an additional 2,328 shares in the last quarter. 47.12% of the stock is owned by institutional investors and hedge funds.
About Insys Therapeutics